were excluded. Total costs to Medicare and hospital-based care (emergency department visits, intensive care unit admissions, and hospital admissions) in the 30 days prior to death, as described in Medicare core quality measures, were determined for each patient and compared using the MannWhitney test for continuous variables (cost) and χ 2 test for categorical variables (all others). 3 A 2-sided P = .05 indicated statistical significance. Regression analyses of risk for hospital-based care and costs were performed, with adjustment for sociodemographic factors (including self-reported race/ethnicity), Charlson comorbidity index score (excluding cancer), and receipt of chemotherapy, radiotherapy, and hospice care. Risks for hospital-based care were calculated by generalized log-linear models using Poisson distribution with robust variance estimates. Linear mixed-effect models accounting for random effects were constructed to assess costs. Analyses were performed from August 31, 2016 , to February 16, 2017 . The University of Alabama at Birmingham institutional review board approved the study and the waiver of patient informed consent.
Results | Of the 12 725 decedents, 1323 (10.4%) had either PMBT (n = 383) or SMBT (n = 940). Sociodemographic characteristics were similar between groups. In the last 30 days of life, patients with SMBT were more likely than those with PMBT to have an emergency department visit (470 [50%] Table 2) . Among those with SMBT, increasing age (RR = 0.92; 95% CI, 0.86-0.99) and Charlson score of 1 or higher (RR = 1.81; 95% CI, 1.47-2.22) were associated with hospitalbased care. Hospital-based care was associated with increased costs for both PMBT ($16 303 increase; P < .001) and SMBT ($13 132 increase; P < .001) ( Table 2) .
Discussion | Hospital-based care was used by 725 of 1323 older patients (54.8%) with malignant brain tumors in the final days of life, which was associated with a $13 000 to $16 000 increase in cost. Patients with SMBT were more likely than those with PMBT to receive hospital-based care, as were men and younger patients. It is possible that less certain disease trajectories in patients with SMBT led to the choice of aggressive care at a juncture not perceived to be the end of life.
4 Furthermore, certain sociodemographic characteristics, such as being male, are consistent risk factors for aggressive end-of-life care, which may represent different preferences as opposed to inequities in care. 5 Comparable rates of intensive care unit admission for patients with PMBT and SMBT are likely attributable to lower relative incidence than in other hospital-based care. High overall rates of hospital-based care and costs may also be attributable to caretakers being unprepared or unequipped to manage common end-of-life symptoms, particularly neurological decline. 6 These findings underscore the need for interventions that facilitate earlier communication about common illness trajectories and care preferences in the brain tumor population-specifically, discussions about how and where the patient would like to manage a foreseeable neurologic decline. 
Out-of-Pocket Costs, Financial Distress, and Underinsurance in Cancer Care
The financial burden of cancer treatment is a wellestablished concern. 1,2 Owing to cost sharing, even insured patients face financial burden and are at risk for worsened quality of life 3 and increased mortality. 4 Underinsured patients 
